Aussie medtech company ResApp Health (ResApp) recently announced news of its sale to Pfizer Australia, a wholly-owned subsidiary of global biopharmaceutical company Pfizer Inc. The proposed acquisition will mean that Pfizer will acquire 100% of the shares in ResApp (by way of a Scheme of Arrangement) for A$0.115...

Translate »